Levofloxacin: a review of its use in the treatment of bacterial infections in the United States (Q35603775)

9 August 2017

1 reference

title

Levofloxacin: a review of its use in the treatment of bacterial infections in the United States (English)

1 reference

9 August 2017

main subject

United States of America

0 references

1 reference

Katherine F Croom

1 reference

9 August 2017

Karen L Goa

series ordinal

1 reference

9 August 2017

publication date

1 January 2003

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

2769-2802

1 reference

Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval

9 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200363240-00008

Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients

21 January 2018

1 reference

12 December 2020

Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer

1 reference

12 December 2020

A randomized, crossover design study of the pharmacology of extended-spectrum fluoroquinolones for pneumococcal infections

1 reference

12 December 2020

Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults

1 reference

12 December 2020

Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: a multicentre, double-blind, randomized study. The Canadian Sinusitis Study Group

1 reference

12 December 2020

Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 gram-positive and -negative bacteria

1 reference

12 December 2020

Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers

1 reference

12 December 2020

Effects of three fluoroquinolones on QT interval in healthy adults after single doses

1 reference

12 December 2020

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

12 December 2020

The safety profile of the fluoroquinolones.

1 reference

12 December 2020

Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses

1 reference

12 December 2020

Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae

1 reference

12 December 2020

Ventilator-associated pneumonia

1 reference

12 December 2020

Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients

1 reference

12 December 2020

Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).

1 reference

12 December 2020

In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae

1 reference

12 December 2020

Prostatitis and urinary tract infection in men: what's new; what's true?

1 reference

12 December 2020

Pharmacokinetic evaluation of oral levofloxacin in human immunodeficiency virus-infected subjects receiving concomitant antiretroviral therapy

1 reference

12 December 2020

Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin

1 reference

12 December 2020

Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial

1 reference

12 December 2020

Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci

1 reference

12 December 2020

Microbiologic effectiveness of time- or concentration-based dosing strategies in Streptococcus pneumoniae

1 reference

12 December 2020

Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes.

1 reference

12 December 2020

Streptococcus pneumoniaeKilling Rate and Post-Antibiotic Effect of Levofloxacin and Ciprofloxacin

1 reference

12 December 2020

QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin

1 reference

12 December 2020

Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections

1 reference

12 December 2020

Nosocomial pneumonia: emerging concepts in diagnosis, management, and prophylaxis

1 reference

12 December 2020

Enantioselective disposition of ofloxacin in humans

1 reference

12 December 2020

Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin

1 reference

12 December 2020

Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia

1 reference

12 December 2020

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

12 December 2020

Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation

1 reference

12 December 2020

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

1 reference

12 December 2020

Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.

1 reference

12 December 2020

Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults

1 reference

12 December 2020

In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe

1 reference

12 December 2020

Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002

1 reference

12 December 2020

Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study

1 reference

12 December 2020

Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.

1 reference

12 December 2020

A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia

1 reference

12 December 2020

Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995

1 reference

12 December 2020

High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm

1 reference

12 December 2020

Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001.

1 reference

12 December 2020

Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents

1 reference

12 December 2020

Levofloxacin-warfarin interaction

1 reference

12 December 2020

Effect of levofloxacin on theophylline clearance during theophylline and clarithromycin combination therapy

1 reference

12 December 2020

Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).

1 reference

12 December 2020

A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection

1 reference

12 December 2020

Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam-based therapy

1 reference

12 December 2020

The clinical pharmacokinetics of levofloxacin

1 reference

12 December 2020

Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients

1 reference

12 December 2020

A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis

1 reference

12 December 2020

Comparative activity of gatifloxacin and other antibiotics against 4009 clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000.

1 reference

12 December 2020

A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia

1 reference

12 December 2020

An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia

1 reference

12 December 2020

Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study

1 reference

12 December 2020

Latest industry information on the safety profile of levofloxacin in the US.

1 reference

12 December 2020

Accumulation of a newly developed fluoroquinolone, OPC-17116, by human polymorphonuclear leukocytes

1 reference

12 December 2020

Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.

1 reference

12 December 2020

Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients

1 reference

12 December 2020

The role of antibiotics in the treatment of chronic prostatitis: a consensus statement

1 reference

12 December 2020

Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects

1 reference

12 December 2020

[Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections]

1 reference

12 December 2020

Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine

1 reference

12 December 2020

A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections

1 reference

12 December 2020

Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial

1 reference

12 December 2020

Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network

1 reference

12 December 2020

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

1 reference

12 December 2020

Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia

1 reference

12 December 2020

The expanding role of fluoroquinolones

1 reference

12 December 2020

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

12 December 2020

In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae

1 reference

12 December 2020

Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit

1 reference

12 December 2020

Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis

1 reference

12 December 2020

Spontaneous Achilles tendon rupture in patients treated with levofloxacin

1 reference

12 December 2020

Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002

1 reference

12 December 2020

BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens

1 reference

12 December 2020

Levofloxacin: an updated review of its use in the treatment of bacterial infections

1 reference

12 December 2020

Fluoroquinolone toxicity profiles: a review focusing on newer agents

1 reference

12 December 2020

Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms

1 reference

12 December 2020

Quinolone activity against anaerobes

1 reference

12 December 2020

Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy

1 reference

12 December 2020

Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials

1 reference

12 December 2020

Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis.

1 reference

12 December 2020

Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity.

1 reference

12 December 2020

In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.

1 reference

12 December 2020

A critical review of the fluoroquinolones: focus on respiratory infections

1 reference

12 December 2020

Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study

1 reference

12 December 2020

Multicenter, Randomized Study Comparing Levofloxacin and Ciprofloxacin for Uncomplicated Skin and Skin Structure Infections

1 reference

12 December 2020

Absence of a pharmacokinetic interaction between digoxin and levofloxacin

1 reference

12 December 2020

The role of antimicrobial therapy in acute exacerbations of chronic bronchitis

1 reference

12 December 2020

Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract

1 reference

12 December 2020

Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans

1 reference

12 December 2020

Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.

1 reference

12 December 2020

Photoreaction potential of orally administered levofloxacin in healthy subjects

1 reference

12 December 2020

Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.

1 reference

12 December 2020

Levofloxacin and warfarin interaction

1 reference

12 December 2020

Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study

1 reference

12 December 2020

Analysis of ciprofloxacin activity against Streptococcus pneumoniae after 10 years of use in the United States

1 reference

12 December 2020

Antipneumococcal activity of grepafloxacin compared to that of other agents by time-kill methodology

1 reference

12 December 2020

Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs

1 reference

12 December 2020

Economic aspects of antibacterial adverse effects

1 reference

12 December 2020

Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis

1 reference

12 December 2020

In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas

1 reference

12 December 2020

Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS284756 (T-3811) tested against non-fermentative Gram-negative bacilli

1 reference

12 December 2020

In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program

1 reference

12 December 2020

Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae

1 reference

12 December 2020

Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002).

1 reference

12 December 2020

Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers

1 reference

12 December 2020

In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections.

1 reference

12 December 2020

Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin

1 reference

12 December 2020

Toxicity of quinolones

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of levofloxacin

1 reference

12 December 2020

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

12 December 2020

Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers

1 reference

12 December 2020

Levofloxacin-induced bilateral Achilles tendonitis

1 reference

12 December 2020

The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci

1 reference

12 December 2020

Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy

1 reference

12 December 2020

Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents

1 reference

12 December 2020

A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin

1 reference

12 December 2020

Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa

1 reference

12 December 2020

Primary targets of fluoroquinolones in Streptococcus pneumoniae.

1 reference

12 December 2020

Mechanisms of fluoroquinolone resistance: an update 1994-1998.

1 reference

12 December 2020

Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology

1 reference

12 December 2020

Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study

1 reference

12 December 2020

Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin

1 reference

12 December 2020

In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates

1 reference

12 December 2020

A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia

1 reference

12 December 2020

Levofloxacin penetrates human monocytes and enhances intracellular killing of Staphylococcus aureus and Pseudomonas aeruginosa

1 reference

12 December 2020

Comparative antianaerobic activity of BMS 284756

1 reference

12 December 2020

Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers

1 reference

12 December 2020

Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

1 reference

12 December 2020

Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis

1 reference

12 December 2020

Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000)

1 reference

12 December 2020

Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001

1 reference

12 December 2020

Mode of action of fluoroquinolones

1 reference

12 December 2020

Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals.

1 reference

12 December 2020

Acute hepatitis associated with oral levofloxacin therapy in a hemodialysis patient

1 reference

12 December 2020

Antimicrobial susceptibility patterns of beta-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997-2000).

1 reference

12 December 2020

10.2165/00003495-200363240-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

9 August 2017

1047701316

0 references

1 reference